Cargando…

Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells

This study aimed to investigate whether the antidiabetic drugs dipeptidyl peptidase 4 (DPP4) inhibitors such as evogliptin and sitagliptin affect the membrane DPP4 (mDPP4) enzymatic activity and immune function of T helper1 (Th1) cells in terms of cytokine expression and cell profiles. The mDPP4 enz...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Hyunyee, Sung, Ji Hyun, Song, Moon Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Applied Pharmacology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921863/
https://www.ncbi.nlm.nih.gov/pubmed/33148870
http://dx.doi.org/10.4062/biomolther.2020.150
_version_ 1783658557843963904
author Yoon, Hyunyee
Sung, Ji Hyun
Song, Moon Jung
author_facet Yoon, Hyunyee
Sung, Ji Hyun
Song, Moon Jung
author_sort Yoon, Hyunyee
collection PubMed
description This study aimed to investigate whether the antidiabetic drugs dipeptidyl peptidase 4 (DPP4) inhibitors such as evogliptin and sitagliptin affect the membrane DPP4 (mDPP4) enzymatic activity and immune function of T helper1 (Th1) cells in terms of cytokine expression and cell profiles. The mDPP4 enzymatic activity, cytokine expression, and cell profiles, including cell counts, cell viability, DNA synthesis, and apoptosis, were measured in pokeweed mitogen (PWM)-activated CD4(+)CD26(+) H9 Th1 cells with or without the DPP4 inhibitors, evogliptin and sitagliptin. PWM treatment alone strongly stimulated the expression of mDPP4 and cytokines such as interleukin (IL)-2, IL-10, tumor necrosis factor-alpha, interferon-gamma, IL-13, and granulocyte-macrophage colony stimulating factor in the CD4(+)CD26(+) H9 Th1 cells. Evogliptin or sitagliptin treatment potently inhibited mDPP4 activity in a dose-dependent manner but did not affect either the cytokine profile or cell viability in PWM-activated CD4(+)CD26(+) H9 Th1 cells. These results suggest that, following immune stimulation, Th1 cell signaling pathways for cytokine expression function normally after treatment with evogliptin or sitagliptin, which efficiently inhibit mDPP4 enzymatic activity in Th1 cells.
format Online
Article
Text
id pubmed-7921863
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Korean Society of Applied Pharmacology
record_format MEDLINE/PubMed
spelling pubmed-79218632021-03-02 Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells Yoon, Hyunyee Sung, Ji Hyun Song, Moon Jung Biomol Ther (Seoul) Original Article This study aimed to investigate whether the antidiabetic drugs dipeptidyl peptidase 4 (DPP4) inhibitors such as evogliptin and sitagliptin affect the membrane DPP4 (mDPP4) enzymatic activity and immune function of T helper1 (Th1) cells in terms of cytokine expression and cell profiles. The mDPP4 enzymatic activity, cytokine expression, and cell profiles, including cell counts, cell viability, DNA synthesis, and apoptosis, were measured in pokeweed mitogen (PWM)-activated CD4(+)CD26(+) H9 Th1 cells with or without the DPP4 inhibitors, evogliptin and sitagliptin. PWM treatment alone strongly stimulated the expression of mDPP4 and cytokines such as interleukin (IL)-2, IL-10, tumor necrosis factor-alpha, interferon-gamma, IL-13, and granulocyte-macrophage colony stimulating factor in the CD4(+)CD26(+) H9 Th1 cells. Evogliptin or sitagliptin treatment potently inhibited mDPP4 activity in a dose-dependent manner but did not affect either the cytokine profile or cell viability in PWM-activated CD4(+)CD26(+) H9 Th1 cells. These results suggest that, following immune stimulation, Th1 cell signaling pathways for cytokine expression function normally after treatment with evogliptin or sitagliptin, which efficiently inhibit mDPP4 enzymatic activity in Th1 cells. The Korean Society of Applied Pharmacology 2021-03-01 2020-11-05 /pmc/articles/PMC7921863/ /pubmed/33148870 http://dx.doi.org/10.4062/biomolther.2020.150 Text en Copyright © 2021, The Korean Society of Applied Pharmacology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Yoon, Hyunyee
Sung, Ji Hyun
Song, Moon Jung
Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells
title Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells
title_full Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells
title_fullStr Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells
title_full_unstemmed Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells
title_short Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells
title_sort effects of the antidiabetic drugs evogliptin and sitagliptin on the immune function of cd26/dpp4 in th1 cells
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921863/
https://www.ncbi.nlm.nih.gov/pubmed/33148870
http://dx.doi.org/10.4062/biomolther.2020.150
work_keys_str_mv AT yoonhyunyee effectsoftheantidiabeticdrugsevogliptinandsitagliptinontheimmunefunctionofcd26dpp4inth1cells
AT sungjihyun effectsoftheantidiabeticdrugsevogliptinandsitagliptinontheimmunefunctionofcd26dpp4inth1cells
AT songmoonjung effectsoftheantidiabeticdrugsevogliptinandsitagliptinontheimmunefunctionofcd26dpp4inth1cells